MeiraGTx Holdings PLC (NASDAQ:MGTX) Stock Has Consensus Price Target of $24.00 According to Brokerages

MeiraGTx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give MeiraGTx a “Moderate Buy” consensus: five of eight covering analysts rate it a buy and three rate it a hold, with an average 12-month price target of $24.
  • The stock opened at $7.99, while the company’s latest quarterly results fell short of estimates: adjusted loss was $0.53 per share versus an expected $0.50 loss, and revenue was $4.81 million versus $6.95 million forecast.
  • Company insiders sold about 145,659 shares worth $1.38 million over the past 90 days, while institutional investors own 67.48% of the stock. The CEO and CFO sales were made under pre-arranged trading plans.
  • MarketBeat previews the top five stocks to own by December 1st.

MeiraGTx Holdings PLC (NASDAQ:MGTX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $24.00.

A number of brokerages have issued reports on MGTX. Royal Bank Of Canada lifted their price objective on MeiraGTx from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Friday, August 14th. The Goldman Sachs Group began coverage on MeiraGTx in a research report on Thursday, September 24th. They set a "neutral" rating and a $16.00 price objective for the company. Wall Street Zen downgraded shares of MeiraGTx from a "buy" rating to a "hold" rating in a research report on Saturday, November 14th. Zacks Research downgraded shares of MeiraGTx from a "strong-buy" rating to a "hold" rating in a report on Friday, September 11th. Finally, Weiss Ratings lowered shares of MeiraGTx from a "hold (c+)" rating to a "hold (c)" rating in a research report on Friday, November 13th.

Read Our Latest Stock Analysis on MGTX

MeiraGTx Trading Down 1.8%

Shares of MGTX opened at $7.99 on Friday. MeiraGTx has a 12 month low of $6.62 and a 12 month high of $15.35. The stock's 50-day moving average is $10.22 and its two-hundred day moving average is $10.38. The company has a debt-to-equity ratio of 0.57, a current ratio of 4.62 and a quick ratio of 4.62. The stock has a market cap of $780.86 million, a PE ratio of 9.99 and a beta of 1.09.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.03). MeiraGTx had a net margin of 19.46% and a return on equity of 85.23%. The firm had revenue of $4.81 million for the quarter, compared to analyst estimates of $6.95 million. Equities analysts forecast that MeiraGTx will post 0.20 earnings per share for the current fiscal year.

Insider Activity at MeiraGTx

In other news, CEO Alexandria Forbes sold 62,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $8.45, for a total value of $523,900.00. Following the completion of the sale, the chief executive officer directly owned 1,239,595 shares of the company's stock, valued at $10,474,577.75. This trade represents a 4.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of the company's stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $9.95, for a total transaction of $557,200.00. Following the completion of the transaction, the chief financial officer owned 852,530 shares in the company, valued at approximately $8,482,673.50. The trade was a 6.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 145,659 shares of company stock valued at $1,375,392 over the last ninety days. Insiders own 7.40% of the company's stock.

Hedge Funds Weigh In On MeiraGTx

A number of hedge funds and other institutional investors have recently modified their holdings of MGTX. Johnson & Johnson purchased a new stake in shares of MeiraGTx during the 2nd quarter worth $89,720,775. BlackRock Inc. acquired a new position in MeiraGTx in the 2nd quarter valued at $64,269,000. Rubric Capital Management LP raised its holdings in shares of MeiraGTx by 13.4% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock worth $60,620,000 after acquiring an additional 824,669 shares during the period. Opaleye Management Inc. increased its position in shares of MeiraGTx by 67.2% during the 2nd quarter. Opaleye Management Inc. now owns 3,550,000 shares of the company's stock worth $47,960,000 after purchasing an additional 1,426,741 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in MeiraGTx by 250.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,147,015 shares of the company's stock valued at $12,617,000 after acquiring an additional 819,599 shares during the period. 67.48% of the stock is currently owned by institutional investors.

About MeiraGTx

(Get Free Report)

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.

Further Reading

Analyst Recommendations for MeiraGTx (NASDAQ:MGTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MeiraGTx Right Now?

Before you consider MeiraGTx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MeiraGTx wasn't on the list.

While MeiraGTx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines